The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The challenges of venetoclax dosing in AML
In this video, Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, briefly discusses the challenge of treating patients with acute myeloid leukemia (AML) with the standard venetoclax dosage due to hematological toxicity, highlighting that a reduced schedule is commonly used. Dr Papayannidis notes that studies presented at the ASH 2025 meeting indicate that reduced dosing is often necessary, particularly in older patients. Additionally, new data suggest that venetoclax-based regimens may benefit newly diagnosed patients fit for standard chemotherapy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
